India's Ranbaxy gets FDA nod for Glycopyrrolate

MUMBAI Aug 24 (Reuters) - Ranbaxy Laboratories (RANB.BO), India's top drugmaker by sales, said on Monday it had final approval from the U.S. Food and Drug Administration to make and market peptic ulcer treatment tablet Glycopyrrolate in two variants.

The tablet is the generic version of Sciele Pharma's Robinul and has annual market sales of $26 million, the Indian firm said in a statement.

Ranbaxy, majority owned by Japan's Daiichi Sankyo (4568.T), plans to launch the tablet in the December quarter. (Reporting by Narayanan Somasundaram; Editing by John Mair)